17.00
-0.36 (-2.07%)
| Previous Close | 17.36 |
| Open | 17.09 |
| Volume | 1,282,318 |
| Avg. Volume (3M) | 2,772,182 |
| Market Cap | 3,725,407,744 |
| Price / Sales | 317.34 |
| Price / Book | 4.44 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2026 |
| Operating Margin (TTM) | -1,105.21% |
| Diluted EPS (TTM) | -2.20 |
| Quarterly Revenue Growth (YOY) | -23.30% |
| Total Debt/Equity (MRQ) | 6.54% |
| Current Ratio (MRQ) | 19.96 |
| Operating Cash Flow (TTM) | -271.99 M |
| Levered Free Cash Flow (TTM) | -155.22 M |
| Return on Assets (TTM) | -28.82% |
| Return on Equity (TTM) | -45.46% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Relay Therapeutics, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -2.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Relative Valuation | NA |
| Financial Health | NA |
| AI Insight | NA |
| Weighted Average | -0.63 |
Select this tab to load the latest available analysis.
|
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 1.48% |
| % Held by Institutions | 105.68% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CATINAZZO THOMAS | - | 18.74 | -17,717 | -332,017 |
| PATEL SANJIV | - | 17.95 | -48,199 | -865,172 |
| Aggregate Net Quantity | -65,916 | |||
| Aggregate Net Value ($) | -1,197,189 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 18.35 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| PATEL SANJIV | Officer | 07 Oct 2026 | Automatic sell (-) | 48,199 | 17.95 | 865,172 |
| CATINAZZO THOMAS | Officer | 06 Oct 2026 | Automatic sell (-) | 17,717 | 18.74 | 332,017 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |